A Phase 3 program of eloralintide in knee osteoarthritis pain and obesity (ENLIGHTEN-4) is registered
Phase IIIP1Primary public evidenceTrial registry record
NCT07353931 lists a start date of 9 February 2026 for a master protocol of Phase 3 placebo-controlled studies of once-weekly eloralintide in adults with osteoarthritis knee pain and obesity or overweight. The registry lists 900 planned participants, 152 locations and primary completion in March 2028.
900
Planned participants, as recorded in the registry
March 2028
Primary completion date listed in the registry
Background and context
What the record describes
ENLIGHTEN-4 is a master protocol covering two independent studies in adults with obesity or overweight and painful knee osteoarthritis. It compares once-weekly eloralintide with placebo, double-blind.
Who can take part and what is measured
Adults need a BMI of at least 27 and knee osteoarthritis with pain. People with any type of diabetes or an active knee infection are excluded. There are two primary endpoints at week 64, percent change in body weight and change in the WOMAC pain subscale score. Participation lasts about 75 weeks.
Reading a pain endpoint
No results are posted. A pain score and a weight change measured in the same trial cannot show by themselves that one drives the other.
Trial record: ClinicalTrials.gov NCT07353931, read on 2026-10-15. Registered plans can change.
P1Primary public evidenceTrial registry record.An official trial registration. A registration shows that a study exists; it does not show that the compound works.
